Lumida
/BFLY
⌘K
Butterfly Network Inc

Butterfly Network Inc

BFLY
$6.62USD↓-5.56%-0.39 today

MARKET CAP

1.7B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $7

52W RANGE

$1
$10

AI Summary

Stalk
Sell NowHigh

BFLY remains in Stage 3 distribution after a decisive support failure at the ~$6.62 level, with lower highs under declining EMAs and volume skewed toward sell‐offs. The medium-term bias is bearish, reinforced by consistent rejections at the 9/21 EMA and accelerating downtrend, while short-term timing favors selling on rallies into the dynamic resistance zone. The long-term uptrend stays intact above major moving averages, but the prevailing distribution structure dominates execution.

  • ↑Revenue jumped 25% YoY to $26.5 M in Q1’26
  • ↑Gross margin improved to 69% from 63% YoY
  • ↓Valuation stretched vs. earnings, signaling downside risk
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Butterfly Network, Inc. (NASDAQ: BFLY) is a pioneering diagnostic imaging company focused on revolutionizing ultrasound technology through handheld devices. The company's innovative Ultrasound-on-Chip™ platform integrates advanced imaging technology with artificial intelligence, making ultrasound accessible in diverse healthcare settings, particularly point-of-care diagnostics. Butterfly is positioned uniquely at the intersection of healthcare innovation and technology, targeting emerging markets while enhancing the overall landscape of medical imaging.

Bull says

  • ↑Revenue jumped 25% YoY to $26.5 M in Q1’26
  • ↑Gross margin improved to 69% from 63% YoY
  • ↑Brazil launch of Butterfly iQ+ and iQ3 expands international footprint
  • ↑AI-driven tools (gestational-age GA tool) and Aleph Neuro tie-ups boost differentiation
  • ↑Strong momentum factors and positive analyst revisions suggest continued upside
  • ↑$138 M cash on hand and 147% YoY surge in embedded revenue support runway

Bear says

  • ↓Valuation stretched vs. earnings, signaling downside risk
  • ↓Adjusted EBITDA loss of $6.1 M in Q1’26 highlights profitability challenges
  • ↓High price volatility may deter institutional investors
  • ↓Heavy reliance on strategic partnerships could delay growth
  • ↓Macroeconomic pressures and tight healthcare budgets may slow sales
  • ↓Negative quality indicators underscore execution and efficiency risks

Investment themes with BFLY

Medical Devices↑ +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-02-2026bullish

Transcript signals

Bull points

  • Butterfly opened 2026 with another strong financial performance: 25% revenue growth, 69% gross margin, and the lowest first quarter net loss since going public, all while maintaining a very strong balance sheet to support future growth.
  • We are excited to be the first company ever to earn FDA clearance of a BlindSweep AI tool, which in two minutes can determine the age of a fetus.
  • The GA tool is expected to unlock new relationships with ministries of health across developing countries, moving beyond the idea of democratizing healthcare to actually delivering on it.

Bear points

  • For the first quarter of 2026, adjusted EBITDA loss was $6.1 million, compared with a loss of $9.1 million for the same period in 2025, an improvement of 32%.
  • We expect an adjusted EBITDA loss in the range of $6 million to $8 million.
  • We expect our adjusted EBITDA loss to be between $21 million and $25 million.
Read full transcript analysis ›